<PAGE>   1
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                  FORM 10-K/A-1
(Mark One)

[X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act
                                    of 1934

                   FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999

                    [ ] Transition report pursuant to Section
                     13 or 15(d) of the Securities Exchange
                    Act of 1934 For the Period From _________
                                 to __________.

                        Commission File Number: 001-14593

                          THE MIIX GROUP, INCORPORATED
             (Exact name of Registrant as specified in its charter)

<TABLE>
<CAPTION>

               DELAWARE                                                      22-3586492
<S>                                                                       <C>
(State or other jurisdiction of incorporation or                           (I.R.S. employer
                  organization)                                           identification number)
</TABLE>


               TWO PRINCESS ROAD, LAWRENCEVILLE, NEW JERSEY 08648
              (Address of principal executive offices and zipcode)

                                 (609) 896-2404
              (Registrant's telephone number, including area code)
             Securities registered pursuant to Section 12(b) of the
                   Act: Common Stock, par value $.01 per share
        Securities registered pursuant to Section 12(g) of the Act: None

         Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter periods as the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                                 YES [X] NO [ ]

         Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]

         The aggregate market value on March 22, 2000 of the voting stock held
by non-affiliates of the registrant was $160,652,552.

         As of March 22, 2000, the number of outstanding shares of the
Registrant's Common Stock was 14,512,083.


                DOCUMENTS INCORPORATED BY REFERENCE IN FORM 10-K

      INCORPORATED DOCUMENTS                      WHERE INCORPORATED

1.Certain portions of the Corporation's           Part III - Items 11, 12 and 13
  Proxy Statement for the Annual Meeting
  of Stockholders to be held
  May 5, 2000 ("Proxy Statement").
<PAGE>   2

                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act
of 1934, the Registrant has duly caused this Amended Report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                                              THE MIIX GROUP, INCORPORATED

                                              By:  /s/ KENNETH KOREYVA
                                                   -----------------------------
                                                       Kenneth Koreyva
                                                       President and Chief
                                                       Executive Officer

                                                        April 10, 2000


Pursuant to the requirements of the Securities Exchange Act of 1934, this
Amended Report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.

<TABLE>
<CAPTION>

    Name                               Title                                     Date
    ----                               -----                                      ----

<S>                                 <C>                                         <C>
/s/ KENNETH KOREYVA                 President, Chief Executive
--------------------
  Kenneth Koreyva                   Officer and Director
                                    (principal executive officer)               April 10, 2000


/s/ THOMAS REDMAN                   Senior Vice President and
--------------------
    Thomas Redman                   Chief Financial Officer
                                    (principal financial and
                                    accounting officer)                         April 10, 2000


        *                              Director
--------------------
Angelo S. Agro, M.D.                                                            April 10, 2000


        *                              Director
--------------------
Harry M. Carnes, M.D.                                                           April 10, 2000


        *                              Director
--------------------
Paul J. Hirsch, M.D.                                                            April 10, 2000


        *                              Director
--------------------
Vincent A. Maressa, Esq.                                                        April 10, 2000


        *                              Director
--------------------
Robert S. Maurer, D.O.                                                          April 10, 2000


        *                              Director
--------------------
A. Richard Miskoff, D.O.                                                        April 10, 2000

</TABLE>



                                                                               2
<PAGE>   3
<TABLE>
<CAPTION>

<S>                                 <C>                                         <C>


             *                         Director

-----------------------
Charles J. Moloney, M.D.                                                        April 10, 2000


             *                         Director
-----------------------
Eileen Marie Moynihan, M.D.                                                     April 10, 2000


             *                         Director
-----------------------
Carl Restivo, Jr., M.D.                                                         April 10, 2000


             *                         Director
-----------------------
Gabriel F. Sciallis, M.D.                                                       April 10, 2000


             *                         Director
-----------------------
Martin L. Sorger, M.D.                                                          April 10, 2000


             *                         Director
-----------------------
Bessie M. Sullivan, M.D.                                                        April 10, 2000


*By: /s/ Kenneth Koreyva
-----------------------
Attorney-in-Fact
</TABLE>


ITEM 14.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.

(a)(1) and (2) and (d)

         The required schedules as identified on the Index to Financial
         Statements on page F-1 of the 10-K are incorporated herein by
         reference. All other schedules for which provision is made in the
         applicable accounting regulation of the Securities and Exchange
         Commission are not required under the related instructions or are
         inapplicable and therefore have been omitted.

(a) (3) and (c) The following exhibits are filed herewith unless otherwise
indicated:

Exhibit
Number                               Description

23.1                                Consent of Ernst & Young LLP



                                                                               3